Texas markets

SYNAPS Dx selects Dallas/Fort Worth, Texas markets as first regions for national commercialization of high-accuracy Alzheimer’s diagnostic test for patients with dementia

DALLAS–(BUSINESS WIRE)–Synaps Dx (SDx), a private company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce that physicians in the Dallas/Fort Worth (DFW) ) will be among the first in the country to offer area residents access to DISCERN™, a minimally invasive diagnostic test. DISCERN assesses factors directly related to the formation of synaptic connections in the brain that impact memory and cognition loss in people living with AD, as well as regulators of amyloid plaque and tau formation, hallmarks from AD to autopsy.

“We are very excited to bring DISCERN to DFW communities and remain impressed with the active role the entire state of Texas is playing in the fight against dementia and Alzheimer’s disease,” said Frank Amato, CEO and president of SDx. “Alzheimer’s disease is a major public health problem in Texas and, according to the Alzheimer’s Association, affects approximately 390,000 Texans. We chose Texas as the first region for the commercial launch of DISCERN based on this high need and the proactive strategies the state has undertaken.

Under the Texas State Plan for Alzheimer’s Disease 2019-2023Texas is implementing strategies to combat AD, including:

  • Improve early detection, reduce risk of disease onset and improve treatment of AD and other dementias

  • Raise awareness among health professionals, caregivers and the public

  • Provide support to caregivers

  • Advance research related to AD and other dementias

  • Collect and evaluate information on prevention and treatment efforts for AD and other dementias.

Amato further cites reports which show approximately 1.4 million unpaid caregivers provided care to Texans with Alzheimer’s disease, which equates to 1.6 billion hours of unpaid care at a cost of approximately $20.6 billion per year. Nationally, the economic burden of Alzheimer’s disease is estimated at more than $290 billion.

“We already have significant interest in the Dallas medical community for DISCERNwhich has demonstrated over 95% specificity and sensitivity in identifying Alzheimer’s disease through long-term, autopsy-validated, blinded clinical trials,” adds Amato, citing the criteria of the National Institutes of Health which define AD at autopsy. “DICERN has received breakthrough designation from the FDA and is the first AD test of its kind to achieve Proprietary Laboratory Analysis (PLA) codes 206U and 207U and has been reimbursed for Medicare Fee-For-Service insured persons. . Currently, there is no FDA-approved test that is as accurate as DISCERN in supporting clinicians’ diagnoses of Alzheimer’s disease, and we look forward to filling that void, starting with the State of Texas. »

SDx has named longtime Dallas resident and business executive Michael Gorton, CEO of Recuro Health, to its advisory board. Recently awarded the Ernst & Young Entrepreneur of the Year Award for Central Plains, Gorton says, “Texans are truly fortunate to be in the first region for national commercialization of this amazing and highly accurate diagnostic test. for Alzheimer’s disease. Thanks to the leadership team’s innovative and entrepreneurial spirit, more Texans will benefit from this important healthcare breakthrough. »


SYNAPS Dx is a private company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The company offers DISCERN™, the first highly accurate and minimally invasive test that allows a clinician to make a definitive diagnosis of AD over other forms of dementia, even in people newly diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients wishing more information can visit https://discertest.com/. For more information about the Company, visit https://www.synapsdx.com/. Contact: [email protected]